Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TGFβ receptor ectodomain-IgG Fc fusion protein, AVID200 DP
AVID200 · 2 trials · 2 indications
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Incidence of treatment related adverse events
| Arm | Type | Description |
|---|---|---|
| Dose Level 1: 180 mg/m2 of AVID200 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation. |
| Dose Level 2: 550 mg/m2 of AVID200 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1 hour administered every three weeks. |
| Dose Level 3: 1100 mg/m2 | EXPERIMENTAL | Intravenous infusion of AVID200 over 1.5 hours administered every three weeks. |
| Dose escalation | OTHER | Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc). Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period). |
| Name | Type | Description |
|---|---|---|
| AVID200 | DRUG | A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ |
Inclusion Criteria: * Patients with a documented (histologically or cytologically proven) solid tumor malignancy that is locally advanced or metastatic * Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability o...
AVID200 is an investigational small molecule being studied for malignant solid tumors and diffuse cutaneous systemic sclerosis, a form of scleroderma. It is in Phase 1 clinical development and is not yet approved by the FDA.
AVID200 is a transforming growth factor beta (TGFβ) inhibitor. It works by inhibiting TGFβ, a protein involved in cell growth and fibrosis, which is relevant to its potential effects in cancer and scleroderma.
AVID200 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and tolerability.
AVID200 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
AVID200 has been studied in two completed Phase 1 trials: NCT03831438 for diffuse cutaneous systemic sclerosis and NCT03834662 for malignant solid tumors. Both trials were conducted in the United States and Canada.
AVID200 is a TGFβ inhibitor, specifically a transforming growth factor beta inhibitor. It is designed to block TGFβ activity, which may play a role in tumor growth and fibrotic diseases like scleroderma.